1. Home
  2. WRAP vs ENTX Comparison

WRAP vs ENTX Comparison

Compare WRAP & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wrap Technologies Inc.

WRAP

Wrap Technologies Inc.

HOLD

Current Price

$1.48

Market Cap

82.7M

Sector

Industrials

ML Signal

HOLD

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.21

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WRAP
ENTX
Founded
2016
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Ordnance And Accessories
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.7M
62.6M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
WRAP
ENTX
Price
$1.48
$1.21
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
179.9K
134.2K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.07
Revenue
$4,672,000.00
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$5.18
Revenue Growth
3.66
N/A
52 Week Low
$1.20
$0.91
52 Week High
$3.23
$3.22

Technical Indicators

Market Signals
Indicator
WRAP
ENTX
Relative Strength Index (RSI) 46.87 49.98
Support Level $1.39 $1.17
Resistance Level $1.60 $1.38
Average True Range (ATR) 0.10 0.09
MACD -0.00 0.02
Stochastic Oscillator 29.79 45.00

Price Performance

Historical Comparison
WRAP
ENTX

About WRAP Wrap Technologies Inc.

Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: